MONTREAL, Nov. 4 /PRNewswire/ -- Chronogen Inc. (http://www.chronogen-inc.com/), a drug discovery company developing human therapeutics to treat age-dependent diseases, announced today the appointment of Max Fehlmann, Ph.D. as its new President and Chief Executive Officer and as a member of its Board of Directors.
Commenting on the appointment, Dr. Yves Fouron, Chairman of the Board of Directors of Chronogen Inc. stated, "We are delighted to have Max join Chronogen as our Chief Executive Officer at this important stage in our evolution. Max brings a wealth of experience relevant to the strategic development of biotechnology businesses. Max's extensive scientific background and operating experience as a senior executive in both private and public Bio- pharmaceutical organizations, will help the company accelerate our product development stage. Prior to this, he was President and CEO of Aster Biotechnologies, which, under his leadership grew from 2 to 35 employees, raised significant private placements and was eventually sold to Zambon Group, a multinational Pharmaceutical Company, who then offered Max the position of R&D director of the entire group". Max holds a Ph.D. from Laval University in Quebec, a DSc from the University of Nice and a MBA from CPA-Mediterrannee in Sophia-Antipolis.
Commenting on his appointment, Dr. Fehlmann said, "I'm very excited about the opportunity which Chronogen represents. With its robust discovery research platform, and its scientific collaborations, the company is well positioned to create value for its drug discovery program targets. My involvement in the biotechnology industry over the last 15 years has given me an appreciation of the combination of great science and effective collaborative business development. I feel that Chronogen has accomplished much in its last year of operation and has the potential to deliver much more. Chronogen is bound to make a number of strategic moves in the near-term".
Chronogen Inc., a privately-held drug discovery company, is a leader in the identification of targets that control the degenerative processes of aging. Based on this innovative approach, the company is developing novel products to control lipid and oxidative stress levels, which are established disease mechanisms in cardiovascular disorders. The control of aging in whole model organisms has provided very valuable assets for a drug discovery technology that will lead to novel and efficacious drugs in significant markets including atherosclerosis, vascular complications of diabetes, and ischemia/reperfusion injuries. Chronogen is headquartered in Montreal, Canada. Further information can be found at http://www.chronogen-/ inc.com
CONTACT: Company Contacts: Max Fehlmann, President & CEO,(514) 521-9595, firstname.lastname@example.org